Syndax Q1 Revenue $64.9M, 50% Transplant Rate Delays Maintenance Restarts
SNDX•Syndax Pharmaceuticals posted Q1 revenue of $64.9 million with a $42.7 million loss (48¢ per share), topping loss estimates but falling short of $70 million revenue forecasts. High 50% transplant penetration in KMT2A patients delayed maintenance restarts by 3–4 months, with 70–80% of patients expected to resume therapy and boost future growth.
1. Q1 Financial Results
Syndax Pharmaceuticals posted Q1 revenue of $64.9 million and a net loss of $42.7 million (48 cents per share), exceeding loss forecasts but missing revenue estimates of $70 million. This performance reflects the initial commercial ramp of its menin inhibitor, ReviForge, in later-line AML patients since its launch last year.
2. Transplant Penetration and Revenue Timing
High transplant rates in KMT2A patients have created short-term headwinds, with approximately 50% of patients pausing ReviForge therapy to undergo transplantation. The average time to resume maintenance therapy is three to four months, with some patients taking up to six months, delaying revenue recognition.
3. Future Growth Drivers
The company expects 70% to 80% of transplanted patients to return to maintenance therapy, driving revenue growth as global site activation and patient enrollment expand. Early-stage penetration in the NPM-1 market and upcoming real-world data on genetic subtypes, including NUP98, should further bolster market share and long-term revenue trajectories.
